[ad_1]
On 23/07/2018, 02:00 clock the stock Roche listed on its domestic market SIX Swiss Ex at the price of 234 CHF. The company belongs to the "pharmaceutical" segment.
Following a proven pattern, we ranked Roche at the current level. The action goes through a rating for 8 factors, each of which is rated "buy", "hold" or "sell". This results in an overall badessment at the last stage.
1. Dividend: Anyone currently investing in Roche shares can earn 2.27 percentage points of additional income, with a dividend yield of 3.55% above the industry average of Biotech & Pharma. As a result, the company's dividends are higher, which translates into a "buy" rating for the Group's distribution policy.
2. Sector Comparison Share price: Roche has a performance of -0.49% over the last 12 months. Similar values in the "Biotech & Pharma" industry rose on average by 23.39%, which means an underperformance of -23.88% in the industry comparison for Roche. The health care sector posted a median return of 19.68% last year. Roche was 20.18 percent below this average. The underperformance in the sector and sector comparisons gives rise to a "sell" rating in this category.
3. Investors: Discussions around Roche on social media platforms send a clear signal about ratings and moods surrounding the stock. Currently, in comments and opinions over the past two weeks, overall negative reviews. In addition, over the past few days, the key value issues have been resolved. Our editorial team comes to the conclusion that the company should be clbadified as a "sale". Finally, in the period elapsed at this level, four trading signals can be determined. The picture shows 0 buy and 4 sell signals. This result ultimately leads to a clbadification as a "sale" share. In summary, the publishers therefore believe that Roche's shares are valued appropriately in terms of investor sentiment as "sell".
Source link
